Opthea Limited - American Depositary Shares (OPT)
Frequently Asked Questions About Opthea Limited - American Depositary Shares (OPT)
Does Opthea have any competitors?
Yes, Opthea Limited faces competition from several biotechnology and pharmaceutical companies developing therapies for retinal diseases, particularly in the area of wet AMD and DME. Competitors may offer established treatments, as well as emerging therapies that could directly compete with Opthea's product candidates like OPT-302.
How can investors learn about Opthea's performance?
Investors can learn about Opthea Limited's performance by reviewing its quarterly and annual financial reports, available on the company's website and filed with the Securities and Exchange Commission (SEC). Additionally, the company conducts investor presentations and conference calls to provide updates on clinical progress and business developments.
How does Opthea fund its research and development?
Opthea Limited funds its research and development through a combination of public equity financing, grants, and collaborations with research institutions. The company has successfully raised capital through its public offerings, which support its clinical trials and operational expenses.
How does Opthea support patient access to its therapies?
Opthea Limited is committed to ensuring patient access to its therapies by engaging in pricing discussions, working with healthcare providers, and potentially exploring patient assistance programs upon the launch of its products. The company emphasizes the importance of affordability and making its treatments accessible to those in need.
What are the potential side effects of OPT-302?
As with any investigational therapy, OPT-302 may have potential side effects, which are being evaluated through clinical trials. Common side effects associated with intravitreal injections may include eye discomfort, increased intraocular pressure, and inflammation. Detailed information on side effects is provided to study participants as part of informed consent.
What challenges does Opthea Limited face?
Opthea Limited faces various challenges typical for biotechnology companies, including the high costs and risks associated with clinical trials, potential regulatory hurdles, and the need to demonstrate the efficacy and safety of its therapies to stakeholders. Additionally, competition from other biotechnology firms developing similar therapies is a significant factor in the landscape.
What distinguishes Opthea from its competitors?
Opthea Limited distinguishes itself through its proprietary approach to targeting multiple pathways involved in retinal disease progression, particularly with its lead candidate OPT-302. This dual-pathway inhibition strategy aims to improve treatment outcomes compared to existing therapies, which typically target a single pathway.
What does Opthea Limited do?
Opthea Limited is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of eye diseases. Their lead product candidate, OPT-302, is an intravitreal therapy targeting age-related macular degeneration (AMD) and other retinal diseases by inhibiting specific pathways involved in the progression of these diseases.
What is OPT-302?
OPT-302 is Opthea Limited's lead investigational therapy designed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. It works by inhibiting the activity of specific growth factors that contribute to abnormal blood vessel growth and inflammation in the eye.
What is Opthea's approach to regulatory approvals?
Opthea Limited follows a rigorous approach to obtaining regulatory approvals for its product candidates, which involves conducting comprehensive clinical trials to demonstrate safety and efficacy. The company works closely with regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA), to ensure compliance with their requirements.
What is Opthea's vision for the future?
Opthea Limited aims to become a leader in the development of innovative treatments for retinal diseases, improving outcomes for patients suffering from conditions like wet AMD and DME. The company is committed to bringing its product candidates through clinical development stages, securing regulatory approvals, and ultimately making its therapies accessible to patients in need.
What is the long-term outlook for Opthea?
The long-term outlook for Opthea Limited is cautiously optimistic, as the company's innovative therapies for retinal diseases enter advanced stages of clinical development. With a strong pipeline and strategic focus on addressing unmet medical needs, Opthea aims to establish itself as a key player in the ophthalmic market, influencing the future of treatments for vision-threatening conditions.
What is the status of Opthea's clinical trials?
As of October 2023, Opthea Limited is conducting late-stage clinical trials to evaluate the safety and efficacy of OPT-302 for treating wet AMD. The company reports progress in its trials and is working towards submitting data to regulatory authorities for potential approvals.
What markets does Opthea target?
Opthea Limited primarily targets the ophthalmic market, focusing on conditions such as wet AMD and diabetic macular edema (DME), which are serious eye disorders leading to vision loss. The total addressable market for these diseases is significant, given the aging population and increasing prevalence of diabetes.
What partnerships does Opthea have?
Opthea Limited has formed collaborations with academic institutions and research organizations to advance its drug development efforts. These partnerships often focus on clinical trial design and execution, helping to leverage external expertise and resources to achieve its research objectives.
What role do American Depositary Shares (ADS) play for Opthea?
American Depositary Shares (ADSs) allow investors in the United States to purchase shares of foreign companies like Opthea Limited more easily. Each ADS generally represents a specific number of ordinary shares and simplifies the process of trading and owning shares of companies listed on non-U.S. exchanges.
When did Opthea Limited go public?
Opthea Limited went public on the Nasdaq under the ticker symbol OPT in July 2020. The move was part of the company's strategy to raise capital to fund its development programs and enhance its visibility in the global biotechnology market.
Where is Opthea Limited based?
Opthea Limited is headquartered in Melbourne, Australia. The company is strategically positioned to leverage Australia's strong biotechnology sector and access to world-class research institutions, facilitating its efforts in drug development and clinical research.
Who are the key personnel at Opthea Limited?
Opthea Limited's leadership team comprises experienced professionals from the biotechnology and pharmaceutical industries, including executives with deep expertise in drug development, regulatory affairs, and commercialization. The Board of Directors includes leaders with a proven track record in the healthcare sector and a commitment to advancing Opthea's strategic goals.
What is the current price of Opthea Limited - American Depositary Shares?
The current price of Opthea Limited - American Depositary Shares is 3.410
When was Opthea Limited - American Depositary Shares last traded?
The last trade of Opthea Limited - American Depositary Shares was at 10:04 am EDT on March 17th, 2025